Suppr超能文献

立体定向放射外科治疗库斯四级前庭神经鞘瘤:一项系统评价和荟萃分析。

Stereotactic radiosurgery for Koos grade IV vestibular schwannoma: a systematic review and meta-analysis.

作者信息

Szymoniuk Michał, Kochański Marek, Wilk Karolina, Miazga Dominika, Kanonik Oliwia, Dryla Aleksandra, Kamieniak Piotr

机构信息

Department of Neurosurgery and Pediatric Neurosurgery, Medical University of Lublin, Ul. Jaczewskiego 8, 20-954, Lublin, Poland.

出版信息

Acta Neurochir (Wien). 2024 Feb 23;166(1):101. doi: 10.1007/s00701-024-05995-2.

Abstract

BACKGROUND

Stereotactic radiosurgery (SRS) is a well-established treatment option for Koos stage I-III vestibular schwannomas (VS), often used as the first line of treatment or after subtotal resection. However, the optimal treatment for Koos-IV VS remains unclear. Therefore, our study aimed to evaluate the effectiveness of SRS as a primary treatment for large VS classified as Koos-IV.

METHODS

A systematic search was performed on December 28th, 2022, based on PubMed, Web of Science, and Scopus according to the PRISMA statement. The review was updated on September 7th, 2023. The risk of bias was assessed using the NIH Quality Assessment Tool. The R software (ver. 4.3.2) was used for all quantitative analyses and preparation of the forest plots. Publication bias and sensitivity analysis were performed to evaluate the reliability of the obtained results.

RESULTS

Among 2941 screened records, ten studies (1398 patients) have been included in quantitative synthesis. The overall tumor control rate was 90.7% (95%CI 86.3-94.4). Kaplan-Meier estimates of tumor control at 2, 6, and 10 years were 96.0% (95% CI 92.9-97.6%), 88.8% (95% CI 86.9-89.8%), and 84.5% (95% CI, 81.2-85.8%), respectively. The overall hearing preservation rate was 56.5% (95%CI 37-75.1). Kaplan-Meier estimates of hearing preservation rate at 2, 6, and 10 years were 77.1% (95% CI 67.9-82.5%), 53.5% (95% CI 44.2-58.5%), and 38.1% (95% CI 23.4-40.7%), respectively. The overall facial nerve preservation rate was 100% (95%CI 99.9-100.0). The overall trigeminal neuropathy rate reached 5.7% (95%CI 2.9-9.2). The overall rate of new-onset hydrocephalus was 5.6% (95%CI 3-9). The overall rates of worsening or new-onset tinnitus and vertigo were 6.8% (95%CI 4.2-10.0) and 9.1% (95%CI 2.1-19.6) respectively. No publication bias was detected according to the used methods.

CONCLUSIONS

Our systematic review and meta-analysis demonstrated a high overall tumor control rate, excellent facial nerve preservation, and low incidence of new-onset or worsened tinnitus and vertigo. However, several drawbacks associated with SRS should be noted, such as the presence of post-SRS hydrocephalus risk, mediocre long-term hearing preservation, and the lack of immediate tumor decompression. Nevertheless, the use of SRS may be beneficial in appropriately selected cases of Koos-IV VS. Moreover, further prospective studies directly comparing SRS with surgery are necessary to determine the optimal treatment for large VS and verify our results on a higher level of evidence. Registration and protocol: CRD42023389856.

摘要

背景

立体定向放射外科治疗(SRS)是一种成熟的治疗库斯(Koos)I - III期前庭神经鞘瘤(VS)的方法,常被用作一线治疗或次全切除术后的治疗手段。然而,对于库斯IV期VS的最佳治疗方法仍不明确。因此,我们的研究旨在评估SRS作为库斯IV期大型VS的主要治疗方法的有效性。

方法

根据PRISMA声明,于2022年12月28日在PubMed、科学网和Scopus上进行了系统检索。该综述于2023年9月7日更新。使用美国国立卫生研究院质量评估工具评估偏倚风险。使用R软件(版本4.3.2)进行所有定量分析并绘制森林图。进行发表偏倚和敏感性分析以评估所得结果的可靠性。

结果

在筛选的2941条记录中,10项研究(1398例患者)纳入了定量合成。总体肿瘤控制率为90.7%(95%CI 86.3 - 94.4)。2年、6年和10年的肿瘤控制的Kaplan - Meier估计值分别为96.0%(95%CI 92.9 - 97.6%)、88.8%(95%CI 86.9 - 89.8%)和%84.5(95%CI 81.2 - 85.8%)。总体听力保留率为56.5%(95%CI 37 - 75.1)。2年、6年和10年的听力保留率的Kaplan - Meier估计值分别为77.1%(95%CI 67.9 - 82.5%)、53.5%(95%CI 44.2 - 58.5%)和38.1%(95%CI 23.4 - 40.7%)。总体面神经保留率为100%(95%CI 99.9 - 100.0)。总体三叉神经病变率达到5.7%(95%CI 2.9 - 9.2)。新发脑积水的总体发生率为5.6%(95%CI 3 - 9)。耳鸣和眩晕加重或新发的总体发生率分别为6.8%(95%CI 4.2 - 10.0)和9.1%(95%CI 2.1 - 19.6)。根据所使用的方法未检测到发表偏倚。

结论

我们的系统评价和荟萃分析表明总体肿瘤控制率高、面神经保留良好,耳鸣和眩晕新发或加重的发生率低。然而,应注意与SRS相关的几个缺点,如存在SRS后脑积水风险、长期听力保留效果一般以及缺乏立即的肿瘤减压。尽管如此,在适当选择的库斯IV期VS病例中使用SRS可能是有益的。此外,有必要进行进一步的前瞻性研究,直接比较SRS与手术,以确定大型VS的最佳治疗方法,并在更高的证据水平上验证我们的结果。注册及方案:CRD42023389856。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验